Speech-Language Pathologists in Mason City, IL Accepting Medicare
4 Speech-Language Pathologists found. Showing 1 - 4
 Madelyn Paige Thomas, MS, CCC-SLP/L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 208 N West Ave, Mason City, IL 62664 Phone: 217-482-5180 |
Rachel Leone, M.S., CCC-SLP/L Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 208 N West Ave, Mason City, IL 62664 Phone: 630-776-3315 |
Kelsi Noel Meeker Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 208 N West Ave, Mason City, IL 62664 Phone: 217-482-3269 |
 Zachary Moore Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 520 N Price St, Mason City, IL 62664 Phone: 217-482-5022 |
News Archive
Study describes new tack in treatment of lung adenocarcinomas
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two already-in-use drugs in laboratory and animal studies, setting the stage for clinical trials of the drugs in patients, researchers at Dana-Farber Cancer Institute and other scientists report in a new study.
Peanut allergy successfully kept at bay with immune-based therapy
Australian researchers from the Murdoch Children's Research Institute have come up with a latest study results showing that peanut allergy could be treated successfully with an immune-based therapy. This new therapy helped children allergic to peanuts eat these nuts with no reactions for up to four years. The study appeared this week in the journal Lancet Child & Adolescent Health.
Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013
Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.
Lilly, Sarah Cannon Research Institute partner to co‑develop investigational oncology compound
Eli Lilly and Company and Sarah Cannon Research Institute today announced a strategic partnership to co‑develop an investigational oncology compound, LY3023414, a PI3K/mTOR dual inhibitor. Under the agreement, SCRI will collaborate with Lilly to provide clinical development expertise and program design, as well as medical oversight and trial management. Patient enrollment for the initial Phase II clinical trial is underway.
› Verified 6 days ago